Current Management and Controversies Surrounding Andropause
Copyright © 2022 Elsevier Inc. All rights reserved..
Andropause is a condition surrounded by controversies, whether it be through its diagnosis or management. As we learn more about the pathophysiology of hypogonadism, our perspectives on the risks and benefits of testosterone therapy have shifted. We attempt to discuss the most modern and relevant points of controversy currently affecting the field. Throughout this review, we discuss the art of diagnosing hypogonadism as well as the association or lack thereof between testosterone replacement therapy and cardiovascular disease, prostate cancer, thrombosis, antiaging effects, exogenous steroid abuse, and diabetes mellitus.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
The Urologic clinics of North America - 49(2022), 4 vom: 21. Nov., Seite 583-592 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mian, Abrar H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3XMK78S47O |
|---|
| Anmerkungen: |
Date Completed 01.11.2022 Date Revised 01.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ucl.2022.07.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348236913 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348236913 | ||
| 003 | DE-627 | ||
| 005 | 20231226035715.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ucl.2022.07.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1160.xml |
| 035 | |a (DE-627)NLM348236913 | ||
| 035 | |a (NLM)36309415 | ||
| 035 | |a (PII)S0094-0143(22)00050-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mian, Abrar H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Management and Controversies Surrounding Andropause |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.11.2022 | ||
| 500 | |a Date Revised 01.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Andropause is a condition surrounded by controversies, whether it be through its diagnosis or management. As we learn more about the pathophysiology of hypogonadism, our perspectives on the risks and benefits of testosterone therapy have shifted. We attempt to discuss the most modern and relevant points of controversy currently affecting the field. Throughout this review, we discuss the art of diagnosing hypogonadism as well as the association or lack thereof between testosterone replacement therapy and cardiovascular disease, prostate cancer, thrombosis, antiaging effects, exogenous steroid abuse, and diabetes mellitus | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Andropause | |
| 650 | 4 | |a Hypogonadism | |
| 650 | 4 | |a TRT | |
| 650 | 4 | |a Testosterone | |
| 650 | 7 | |a Testosterone |2 NLM | |
| 650 | 7 | |a 3XMK78S47O |2 NLM | |
| 700 | 1 | |a Yang, David Y |e verfasserin |4 aut | |
| 700 | 1 | |a Kohler, Tobias S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Urologic clinics of North America |d 1974 |g 49(2022), 4 vom: 21. Nov., Seite 583-592 |w (DE-627)NLM000207489 |x 1558-318X |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2022 |g number:4 |g day:21 |g month:11 |g pages:583-592 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ucl.2022.07.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2022 |e 4 |b 21 |c 11 |h 583-592 | ||